"The labyrinthine complexities of healthcare insurance, often masked by seemingly minor delays, can have devastating, life-altering consequences. Kenney Blewett’s story is a stark reminder that bureaucratic red tape can tragically intersect with human suffering."
The American healthcare system, a marvel of medical innovation, is increasingly burdened by administrative complexities that can impede access to vital care. For individuals battling chronic and life-threatening conditions, the system’s intricacies can transform a necessary prescription into an insurmountable obstacle. Kenney Blewett, a resident of Kyle, Texas, tragically exemplified this reality. Diagnosed with lung disease over a decade ago, his condition worsened significantly this year, leading to severe breathing difficulties that left him feeling as though he couldn’t breathe. These episodes, described by his wife, Cindy, as "the scariest thing in the world," became more frequent and debilitating, impacting even the simplest daily tasks. His declining health, a consequence of decades of smoking, was evident in his significant weight loss and isolation, prompting a doctor to note the alarming resemblance to advanced cancer. It was in this context that a new, potentially life-improving medication was prescribed for his chronic obstructive pulmonary disease (COPD), only for its delivery to be stalled by an "insurance issue." This delay, however brief in bureaucratic terms, preceded a profound personal tragedy, highlighting the critical need for systemic reform in healthcare access.
Blewett’s pulmonologist prescribed a new medication on June 2 to alleviate his severe breathing issues, a direct result of his chronic obstructive pulmonary disease (COPD). However, this critical prescription was not immediately filled. Two days after his doctor’s appointment, an email from Walgreens informed Blewett that the medication’s delivery was delayed due to an ongoing insurance issue. This news arrived just two months before Cindy would recount her husband’s death, her voice heavy with the wish that they could have known if the medication would have made a difference. "He was hopeful that it would work," she stated, her words echoing the profound sense of loss and the unanswered question of what might have been.
Insurance delays and denials have become a pervasive and deeply problematic aspect of the American healthcare landscape. A January KFF Health Tracking Poll revealed that nearly 70% of adults consider these bureaucratic hurdles a "major problem" when seeking medical care. This sentiment underscores a widespread frustration with a system that, despite its advancements, frequently places administrative obstacles between patients and the treatments they need.
In an effort to address these persistent issues, the Trump administration announced a highly publicized industry pledge in June 2025. This voluntary agreement, signed by numerous major health insurers, aimed to dismantle some of the barriers that hinder patients’ access to doctor-recommended care. However, the voluntary nature of this pledge, coupled with the absence of penalties for non-compliance, has raised questions about its efficacy. A subsequent report by KFF Health News in July indicated that some insurers who had signed the pledge were not fully implementing the promised initiatives as originally outlined, suggesting that meaningful change remains elusive.
In the absence of comprehensive federal reform, lawmakers in many states, including Texas, have taken steps to regulate the insurance industry and mitigate delays and denials. However, a significant portion of the population, particularly those with traditional Medicare policies and employer-sponsored health plans—which collectively cover more than half of all Americans—fall outside the purview of state jurisdiction, leaving them subject to federal regulations and the broader, often opaque, insurance landscape.
The complexities of navigating these state and federal insurance regulations are not lost on those working on the front lines of healthcare. Medical office staff and pharmacy employees often find the patchwork of rules and guidelines confusing. This challenge is poised to intensify with the increasing integration of artificial intelligence into the processes of approving and processing insurance claims, potentially introducing new layers of complexity for both providers and patients.
Matt Toresco, CEO of ArchÅ, a patient advocacy and consulting company, expressed the sentiment that the situation has "just gotten completely out of hand." He emphasized the urgent need for enhanced support systems to assist patients in overcoming these insurance hurdles. The Blewett family’s experience serves as a poignant illustration of the monumental task patients and their caregivers face when attempting to navigate these intricate systems.
Cindy Blewett has tirelessly sought answers from various entities, including Medicare, Kenney’s private Part D drug plan, his pulmonologist’s office, and Walgreens. Despite her efforts, questions linger regarding responsibility for the medication delay and how such a holdup could have been prevented. Her profound sorrow is amplified by the agonizing question of whether her husband would have made the tragic decision to end his life on the evening of June 7, had the COPD flare-up he experienced that afternoon been avoidable through timely medication.
During the first week of June, Kenney Blewett repeatedly inquired about the readiness of his prescription for a liquid medication to be inhaled via his nebulizer machine. Cindy initially harbored no immediate concern about the delay. However, it is noteworthy that Walgreens had undergone significant changes following its acquisition by a private equity firm, leading to widespread job cuts, according to the Private Equity Stakeholder Project. Cindy observed that their local Walgreens pharmacy in Kyle appeared to be understaffed for months, resulting in slower prescription fulfillment.
When Cindy contacted the pharmacy a few days after Kenney’s appointment to ascertain the reason for the insurance delay, she was informed that the prescription required prior authorization. This process, also known as preapproval or precertification, is a widely employed practice by health insurers, necessitating medical providers to obtain permission before a patient can receive covered treatment. The challenge for Cindy was identifying which of Kenney’s multiple insurance policies mandated prior authorization for this specific medication.
For years, Cindy had managed Kenney’s complex insurance portfolio. He was covered by Medicare Parts A and B, the federal health insurance program for individuals aged 65 and older or those with disabilities. Additionally, he held a private Part D plan for drug costs through Wellcare Value Script and a Medicare supplement plan, or "Medigap" plan, through Blue Cross and Blue Shield of Texas, which covered other out-of-pocket expenses.
Cindy’s initial assumption was that Kenney’s Part D plan had initiated prior authorization. However, due to the nature of the medication—a liquid inhaled through a nebulizer—it fell under Medicare Part B’s durable medical equipment benefit, rather than Part D. The Medicare agency informed Cindy that they had no record of this prescription being billed to Kenney’s Part B policy. Representatives for Centene, the parent company of Wellcare Value Script, declined to comment on the matter.
Following Kenney’s death, Cindy’s attempts to gain clarity at the Walgreens pharmacy were met with inconsistent information. An employee explained that the prescription had been submitted to Medicare Part B but lacked a necessary diagnostic code from the physician. Carmen Lopez, a Walgreens spokesperson, stated that the company could not comment on individual cases. Subsequently, a Walgreens district pharmacy supervisor contacted Cindy, relaying that the pharmacy had attempted to process the prescription through Part B on the day of the pulmonologist’s appointment but had not received the required diagnostic code from the physician. The supervisor claimed Walgreens had sent a request for this code to the pulmonologist’s office later that day. However, an employee at Dr. Rajesh Shetty’s practice, LungDocs, informed Cindy that they had not received any fax from Walgreens requesting a diagnostic code for the prescription. Kenney’s Medigap plan would not have been a factor, as these policies do not require prior authorization. "Short of getting attorneys involved," Cindy lamented, "I’m not sure how to find out what really happened."
The confusion surrounding the distinctions between Medicare Part B and Part D coverage is a common issue, according to Mike Hess, senior director of advocacy and regulatory affairs at the COPD Foundation. He noted that Medicare’s increasing complexity often leads to misunderstandings, even among healthcare professionals. The anticipated integration of artificial intelligence into the preapproval process is expected to further complicate navigation for Medicare beneficiaries, physicians, and patients alike.
Historically, traditional Medicare has utilized prior authorization sparingly, unlike Medicare Advantage plans. However, in January, Medicare initiated a pilot program in six states—Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington—testing the application of AI for preapproving certain healthcare services. While CMS Administrator Mehmet Oz described the program as an effort to "root out waste in Original Medicare," physicians and patients report that it is creating additional administrative burdens and leading to inappropriate denials. Although the pilot program does not currently impose prior authorization requirements on COPD medications, industry experts foresee its expansion to encompass more services and states.
On the evening of June 7, hours after Kenney’s final COPD flare-up, Cindy heard a gunshot from their bedroom. She discovered her husband’s body, a tragic culmination of his long struggle with deteriorating health and mental health challenges. He had a prior suicide attempt years earlier, and his worsening physical condition exacerbated his psychological distress. In a note left behind, Kenney expressed his deep love for Cindy and their family but stated his health was too poor to continue living. Tragically, a second COPD medication, ordered directly from the manufacturer by his pulmonologist during the June 2 appointment, arrived weeks after his suicide. "Perhaps, just perhaps," Cindy reflected, "if he had received both medications in a timely manner, he would be here today, and we would have had many more years together."
If you or someone you know may be experiencing a mental health crisis, contact the 988 Suicide & Crisis Lifeline by dialing or texting 988.
